A prospective study of the efficacy and the safety of the COVID-19 vaccines in NSCLC patients with UFT as postoperative adjuvant chemotherapy
Not Applicable
- Conditions
- on-small-cell lung cancer
- Registration Number
- JPRN-UMIN000047380
- Lead Sponsor
- Kobe University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who have a history of COVID-19. 2. Patients who have any other infectious diseases under treatment. 3. Patients who receive immunosuppressive agents 4. Patients who receive treatment for other malignant diseases.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The IgG against the S1 subunit of spike protein
- Secondary Outcome Measures
Name Time Method